Prosecution Insights
Last updated: November 20, 2026
Application No. 18/561,591

RESIN COMPOSITION, PREPREG USING SAME, FILM PROVIDED WITH RESIN, METAL FOIL PROVIDED WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD

Final Rejection §103
Filed
Nov 16, 2023
Priority
May 17, 2021 — JP 2021-083148 +1 more
Examiner
XU, JIANGTIAN
Art Unit
1762
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Panasonic Holdings Corporation
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
235 granted / 363 resolved
At TC average
Strong +36% interview lift
Without
With
+36.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
73 currently pending
Career history
429
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
56.8%
+16.8% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 363 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Groups II-VIII (claims 12-18) are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 6/18/2026. Response to Amendment The amendment filed on 9/15/2026 has been entered. Claim(s) 1, 5 and 9 is/are currently amended. Claim(s) 2, 6 and 8 has/have been cancelled. Claim(s) 1, 3-5, 7 and 9-18 is/are pending with claim(s) 12-18 withdrawn from consideration. Claim(s) 1, 3-5, 7 and 9-11 is/are under examination in this office action. Response to Arguments Applicant's argument filed on 9/15/2026, with respect to 103 rejection has been fully considered but is not persuasive. Applicant argued that the range disclosed in Tohjima represents the amount of the additive relative to the compound represented by Formula (1) of the curable resin composition as a reference, but does not define the proportion of component B based on 100 parts by mass of the total amount of components A, B, and C, as required by the present claims. In response, contrary to the applicant’s assessment, the range disclosed in Tohjima does not represent the amount of the additive relative to the compound represented by Formula (1) of the curable resin composition. Instead, the range of 0-700 parts by mass is “based on 100 parts by mass of the curable resin composition” [0099]. The “curable resin composition” includes the compound represented by Formula (1) [0014 [7]], the additive (hydrogenated styrene-isoprene-styrene copolymer), and an active alkene-containing resin [0069] which can be a maleimide resin [0081]. Thus, Tohjima’s “curable resin composition” includes all of the claimed components (A), (B) and (C), not just the components (A). The amount of 0-700 parts of additive (hydrogenated styrene-isoprene-styrene copolymer) based on 100 parts by mass of the curable resin composition overlaps the claimed content of the styrenic polymer (B) of 5 to 50 parts by mass with respect to 100 parts by mass of a sum of the hydrocarbon-based compound (A), the styrenic polymer (B), and the reactive compound (C). Applicant argued that as a demonstration of criticality of the claimed invention, the present specification describes that combining component A with component B, which is solid at 25 °C makes it possible to suppress surface tackiness while maintaining low dielectric properties, heat resistance, and low thermal expansion, and that the incorporation of component C can impart properties such as adhesion. The Examples of the present application also demonstrate the performance advantages obtained by combining these components in the critically specified proportions (see, e.g., paragraphs [0015] and [0069] and the Examples of the present application). In response, to establish unexpected results over a claimed range, applicants should compare a sufficient number of tests both inside and outside the claimed range to show the criticality of the claimed range. In re Hill, 284 F.2d 955, 128 USPQ 197 (CCPA 1960), MPEP 716.02(d). Applicant failed to do so. Paragraphs [0015] and [0069] cited by the applicant do not contain any concrete data. Applicant did not show which experimental data supports the criticality. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tohjima et al (US 20230002547 A1). Regarding claims 1, 3-4 and 7-8, Tohjima teaches a curable resin composition comprising a compound of formula (1): PNG media_image1.png 200 400 media_image1.png Greyscale Wherein R represents a hydrocarbon group having 1 to 10 carbon atoms or a halogenated alkyl group; m represents an integer of 0 to 3; n represents a repeating unit and satisfies 1≤n≤20, and p represents a repeating unit and satisfies 0≤p≤20; Y is optional; X can be PNG media_image2.png 200 400 media_image2.png Greyscale S represents a hydrocarbon group having 1 to 3 carbon atoms; and a represents an integer of 0 to 4 [0011-0013]. Thus, the above formula (1) is the same as the claimed formula (2) when the above a=0, p=0, m=0. The claimed formula (2) meets the claimed formula (1) in claim 1. Tohjima’s Example 2 teaches a compound which is exactly the same as the claimed formula (2) [0121]: PNG media_image3.png 200 400 media_image3.png Greyscale Tohjima teaches that the curable composition can comprise an additive which can be styrene-based thermoplastic elastomers such as hydrogenated styrene-isoprene-styrene copolymer [0099], which reads on the claimed styrenic polymer (B) as specified in claims 3-4. It would have been obvious to one of ordinary skill in the art at the time of filing to select hydrogenated styrene-isoprene-styrene copolymer as the additive in Tohjima’s composition, as it is expressly disclosed as being useful in this capacity. It has been established that selection of a known material based on its suitability for its intended use is prima facie obvious (Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945)). See MPEP 2144.07. Tohjima teaches an active alkene-containing resin [0069] which can be a maleimide resin [0081] which reads on the claimed compound (C) as specified in claim 7. It would have been obvious to one of ordinary skill in the art at the time of filing to select a maleimide resin as the active alkene-containing resin in Tohjima’s composition, as it is expressly disclosed as being useful in this capacity. It has been established that selection of a known material based on its suitability for its intended use is prima facie obvious (Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945)). See MPEP 2144.07. Tohjima teaches that the additive (hydrogenated styrene-isoprene-styrene copolymer) is more preferably 0-700 parts by mass based on 100 parts by mass of the curable resin composition [0099]. Thus, the amount of additive (hydrogenated styrene-isoprene-styrene copolymer) overlaps the claimed content of the styrenic polymer (B) of 5 to 50 parts by mass with respect to 100 parts by mass of a sum of the hydrocarbon-based compound (A), the styrenic polymer (B), and the reactive compound (C). Regarding claim 5, Tohjima teaches that the additive (hydrogenated styrene-isoprene-styrene copolymer) is more preferably 0-700 parts by mass based on 100 parts by mass of the curable resin composition [0099]. This amount overlaps the claimed content of the hydrocarbon-based compound (A1) of 20 to 80 parts by mass with respect to 100 parts by mass of a total mass of the hydrocarbon-based compound (A1) and the styrenic polymer (B). A prima facie case of obviousness exists where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" (MPEP 2144.05.I). Regarding claim 9, Tohjima teaches that the active alkene-containing resin (maleimide resin) is preferably 0.5-3 times by mass relative to the usage amount of the compound represented by the formula (1) [0070]. Thus, the amount of maleimide resin overlaps the claimed content of the reactive compound (C) of 1 to 40 parts by mass with respect to 100 parts by mass of a sum of the hydrocarbon-based compound (A1), the styrenic polymer (B), and the reactive compound (C). Regarding claim 10, Tohjima teaches that inorganic fillers may be added to the curable resin composition [0098]. Regarding claim 11, Tohjima teaches that the curable resin composition may contain a phosphorus-containing compound as a flame retardation-imparting component [0095]. Conclusion THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JIANGTIAN XU whose telephone number is (571)270-1621. The examiner can normally be reached Monday-Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones can be reached on (571) 270-7733. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JIANGTIAN XU/Primary Examiner, Art Unit 1762
Read full office action

Prosecution Timeline

Nov 16, 2023
Application Filed
Jul 16, 2026
Non-Final Rejection mailed — §103
Sep 15, 2026
Response Filed
Nov 04, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799277
APROTIC CATALYSTS FOR THE HYDROLYSIS / CONDENSATION OF ORGANOALKOXYSILANES
3y 11m to grant Granted Nov 17, 2026
Patent 12780993
CROSSLINKED ORGANIC SILICON RESIN, A METHOD FOR PREPARING THE SAME, AND A COSMETIC
2y 10m to grant Granted Nov 03, 2026
Patent 12767735
METHOD OF MANUFACTURING POLYMERIZABLE COMPOSITION, POLYMERIZABLE COMPOSITION, AND CURED PRODUCT
3y 5m to grant Granted Oct 20, 2026
Patent 12758899
POLYETHYLENIMINE AS A NEW EMULSION BREAKER FOR QUENCH WATER SYSTEMS
1y 8m to grant Granted Oct 13, 2026
Patent 12752249
Preparation Method Of High-Efficiency Gel For Seawater Desalination
3y 1m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+36.1%)
3y 3m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 363 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month